



SmartPA Criteria Proposal

Drug/Drug Class:	Clobazam Agents Clinical Edit
First Implementation Date:	May 23, 2013
Revised Date:	August 5, 2021
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of clobazam agents

Why Issue Selected: Clobazam is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS). LGS is a severe form of epilepsy usually beginning before four years of age. Seizure types include tonic, atonic, atypical absence, and myoclonic. As children with LGS grow older, the seizure types change. Some children have developed normally when LGS begins, but then lose skills, sometimes dramatically, due to uncontrolled seizures. By age six, most children with this syndrome have some degree of mental retardation. Behavioral problems are also common, ranging from hyperactivity to autistic behaviors. Treatment of LGS includes a variety of anti-epileptic medications. Clobazam products provide additional treatment options for LGS and are now available in tablet, liquid, and film formulations.

Although it does not have an FDA approved indication, clobazam is considered a first line agent for the treatment of Dravet syndrome. Dravet syndrome is a rare form of epilepsy typically appearing during the first year of life with frequent or prolonged seizures. Previously known as Severe Myoclonic Epilepsy of Infancy (SMEI), Dravet Syndrome affects 1:15,700 children, 80% of whom have a mutation in their *SCN1A* gene. Children with Dravet syndrome typically experience poor development of language and motor skills, hyperactivity, and difficulty relating to others. Although an off-label indication, MO HealthNet will approve clobazam for use in Dravet syndrome.

Program-Specific Information:

Date Range FFS 1-1-2020 to 12-31-2020			
Drug	Claims	Spend	Avg Spend per Claim
ONFI 2.5 MG/ML SUSPENSION	3,131	\$580,372.38	\$185.36
ONFI 10 MG TABLET	3,386	\$174,320.38	\$51.48
ONFI 20 MG TABLET	980	\$136,551.23	\$139.33
SYMPAZAN 5 MG FILM	0	-	-
SYMPAZAN 10 MG FILM	2	\$3,304.74	\$1,652.37
SYMPAZAN 20 MG FILM	0	-	-

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Clobazam agents
- Age range: All appropriate MO HealthNet participants aged 2 years or older

Approval Criteria

- Participant aged 2 years or older **AND**
- Documented diagnosis of Lennox-Gastaut syndrome (LGS) **OR**
- Documented diagnosis of Dravet Syndrome **OR**
- Documented compliance on current therapy (defined as 90/120 days) **OR**
- Approval by Clinical Consultant Review
- For Sympazan: Documented therapeutic trial of generic clobazam tablets or solution in the past year

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

X

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

1 year

References

- Facts & Comparisons. Clobazam Oral. Accessed February 11, 2021.
- IPD Analytics. CNS: Epilepsy/Seizure Disorder. Accessed February 11, 2021.
- Dravet Syndrome Foundation. What is Dravet Syndrome? <https://www.dravetfoundation.org/what-is-dravet-syndrome/>. Accessed February 11, 2021.
- Wirrell EC, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. *Pediatr Neurol.* 2017;68:18-34.e3. doi:10.1016/j.pediatrneurol.2017.01.025

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.